EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome

Haiping Zhang, Julei Wang, Xiaoxiao Li, Dongfeng Zhang, Yingxue Qi, Qin Zhang, Ningning Luo, Xiaoou Wang, Tuo Wang

World Journal of Surgical Oncology · 2024

DOI: 10.1186/s12957-024-03463-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Haiping Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: ErbB Receptors, Oncogene Proteins, Fusion, Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epidermal growth factor receptor ( EGFR) fusions are rare but potentially actionable oncogenic drivers across multiple solid tumors. However, the distribution and molecular characteristics of EGFR fusions in Chinese patients with solid malignancies have not been explored.

Methods

Panel-based next-generation sequencing (NGS) data of 35,023 patients with various types of solid tumors was collected and analyzed from the Simcere Diagnostics (Nanjing, China) database. A 9563-patient cohort was derived from The Cancer Genome Atlas (TCGA) to explore the relationship between EGFR fusion status and overall survival (OS).

Results

In this study, prevalence of functional EGFR fusions was 0.303% (106/35,023) in total across solid tumors, which occur more commonly in gastroesophageal junction cancer (1/61, 1.613%), followed by medulloblastoma (1/66, 1.515%) and glioma (33/2409, 1.370%). Analysis showed a prevalence for fusion partners in different tumor types. The top 3 co-mutant genes with EGFR fusion were TP53 (mutation frequency, MF: 65%), BRCA2 (MF: 43%), and ALK (MF: 41%). Furthermore, patients in the EGFR fusion group had a significantly shorter OS than those in the non- EGFR fusion group ( p < 0.0001) in the TCGA cohort, suggesting that EGFR fusion might be a high-risk factor for poor prognosis.

Conclusions

Our study is the first retrospective analysis of EGFR fusions in a large-scale solid tumor population, which may provide a reference for future EGFR-TKI clinical trials with EGFR fusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsOncogene Proteins, FusionNeoplasmsHigh-Throughput Nucleotide SequencingHumansMaleFemalePrognosisSurvival RateMiddle AgedAdultChinaBiomarkers, TumorFollow-Up StudiesBRCA2 ProteinTumor Suppressor Protein p53Anaplastic Lymphoma KinaseAgedYoung AdultMutationAdolescentRetrospective StudiesEast Asian People

Stichwörter der Autor:innen

EGFR fusionClinical outcomeMolecular characteristicsNext-generation sequencingSolid tumors

Substanzen

ErbB ReceptorsEGFR protein, humanOncogene Proteins, FusionBiomarkers, TumorTP53 protein, humanBRCA2 ProteinTumor Suppressor Protein p53BRCA2 protein, humanALK protein, humanAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Neurosurgery, Second Affiliated Hospital of Air Force Military Medical University, Xi'an, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Department of Thoracic Oncology, Linfen Center Hospital, Linfen, China.
  • Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
  • Health Education Promotion Department, Shenyang Stomatological Hospital, Shenyang, China.

Zitieren

APA

Zhang, H., Wang, J., Li, X., Zhang, D., Qi, Y., Zhang, Q., Luo, N., Wang, X., & Wang, T. (2024). Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03463-w

Vancouver

Zhang H, Wang J, Li X, Zhang D, Qi Y, Zhang Q, et al. Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03463-w

BibTeX
@article{Zhang2024,
  author = {Zhang, Haiping and Wang, Julei and Li, Xiaoxiao and Zhang, Dongfeng and Qi, Yingxue and Zhang, Qin and Luo, Ningning and Wang, Xiaoou and Wang, Tuo},
  title = {Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome},
  journal = {World Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1186/s12957-024-03463-w}
}
Kostenlos starten →